ABSTRACT
Alzheimer’s disease (AD) genome-wide association studies (GWAS), typically based on clinical phenotypes, have identified numerous risk loci, yet linking these variants to brain changes and molecular processes remains challenging. We developed a DNE-xQTL framework integrating deep learning-derived dimensional neuroimaging endophenotypes (DNEs) with comprehensive brain molecular quantitative trait loci (xQTL) to dissect genetic pathways underlying AD– and aging-related brain variation. By performing GWAS on seven DNEs and applying integrative computational analyses, we biologically annotated each DNE and prioritized xQTL-supported gene targets. This approach both enhanced interpretation of established AD loci through DNE-mediated annotations and revealed underexplored regulatory pathways, organizing 209 candidate genes into evidence-based tiers. We highlight three regulatory clusters: glutamate-receptor and mitochondrial pathways implicating excitatory-neuron vulnerability, SREBP2-associated cholesterol homeostasis linked to vascular dysfunction, and primary-cilia-associated transport implicated in aging. By connecting pre-symptomatic brain alterations to molecular targets and relevant cell types, this framework may inform earlier risk stratification before clinical neurodegeneration occurs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by NIH/NIA R01AG076901 and R01AG086467(G.W., R.L.), a FunGen-AD Consortium Grant U01AF072572 (G.W., R.F., P.L.), a grant from The Urbut Family Foundation (G.W.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study uses only de-identified human data obtained from established research repositories (e.g., Synapse, UK Biobank). Access requires institutional approval, and these datasets are not considered human subjects research under federal regulations; IRB approval was therefore not required. All analyses were performed exclusively on summary statistics, with detailed data sources and accession information provided in Tables S1 and S2.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This version of the manuscript includes minor typographical corrections in the 'Cell-specific roles of synaptic dysfunction and excitotoxicity in neurodegenerative disorders' section and revised figure legends to improve clarity and consistency.
Data Availability
All data supporting the findings of this study are provided in the main text and Supplementary Information. Summary statistics generated by the FunGen-xQTL project will be made available upon publication of the accompanying consortium manuscript. The complete analysis codebase, including workflows for fine-mapping, colocalization, TWAS, and functional enrichment, is available at https://github.com/rl3328/DNE_xQTL_paper.
